secwatch.observer — SEC 8-K summary
======================================

Issuer:     UNITED THERAPEUTICS Corp (UTHR)
CIK:        0001082554
Form:       8-K
Filed at:   2022-05-04T23:59:59+00:00
Accession:  0001082554-22-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

United Therapeutics Q1 revenue up 22% to $461.9M; diluted EPS $5.03 vs $0.61 YoY
--------------------------------------------------------------------------------

- Q1 revenue $461.9M (+22% YoY) driven by Tyvaso ($172M, +40%) and Unituxin ($55.6M, +27%) on label expansion and Japan launch.
- Net income $239.9M (diluted EPS $5.03) vs $28.3M ($0.61) in Q1 2021; earnings surge primarily due to strong revenue and lower R&D spend.
- Tyvaso DPI NDA under FDA review with decision expected in May 2022; company awaits outcome of citizen petition and inspection issues.
- Phase 3 TETON 1 & 2 studies for IPF, PERFECT for PH-COPD, and ADVANCE trials for ralinepag are enrolling or commencing.
- Orenitram revenue grew 14% YoY to $82.8M on volume and price; Remodulin flat at $131.7M with U.S. decline offset by international orders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/0001082554-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1082554/000108255422000014/uthr-20220504.htm
  HTML page:      https://secwatch.observer/filing/0001082554-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer